Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium (99mtc) succimer
- Development stage
- Unknown
- Lead developer
- CISBIO
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Renocis is a cold kit for the preparation of technetium (99mTc) succimer (DMSA) injection, a diagnostic radiopharmaceutical used in nuclear medicine. The kit contains succimer (dimercaptosuccinic acid) as the active ingredient, which, upon reconstitution with sodium pertechnetate (99mTc) solution, forms a technetium (99mTc) succimer complex. This radiopharmaceutical is indicated for static renal imaging, including the study of renal cortex morphology, individual kidney function, and the location of ectopic kidneys. Following intravenous administration, the technetium (99mTc) succimer complex localizes in high concentrations in the renal cortex, allowing for scintigraphic evaluation of renal parenchymal disorders.
- Brand names
- Renocis
- Other names
- dimercaptosuccinic acidDMSAmeso-2,3-dimercaptosuccinic acidRENOCIS cold kitsuccimertechnetium (99mTc) dimercaptosuccinic acidtechnetium (99mTc) succimer complextechnetium [99mTc] dimercaptosuccinic acidtechnetium [99mTc] succimertechnetium tc 99m succimertechnetium tc-99m succimer
02
Targets
LRP2 (Low-density lipoprotein receptor-related protein 2)SLC20A1 (Sodium-dependent phosphate transporter 1)AMBP (Alpha-1-microglobulin)A2M (Alpha-2-macroglobulin)CUBN (Cubilin (intrinsic factor-vitamin B12 receptor))
Beyond the preview
Go deeper on technetium (99mtc) succimer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium (99mtc) succimer.